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over ADHD and Pediatric
Stimulant Pharmacotherapy
Rick Mayes, Ph.D., Catherine Bagwell, Ph.D.,
and Jennifer Erkulwater, Ph.D.
Attention Deficit Hyperactivity Disorder (ADHD) holds the distinction of
being both the most extensively studied pediatric mental disorder and one of
the most controversial.1 This is partly due to the fact that it is also the most
commonly diagnosed mental disorder among minors.2 On average, one in ev-
ery ten to 15 children in the U.S. has been diagnosed with the disorder and
one in every 20 to 25 uses a stimulant medication—often Ritalin, Adderall,
or Concerta—as treatment.3,4 The biggest increase in youth diagnosed with
ADHD and prescribed a stimulant drug occurred during the 1990s, when the
prevalence of physician visits for stimulant pharmacotherapy increased
five-fold.5-8 This unprecedented increase in U.S. children using psychotropic
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This overview is drawn from our new book, Medicating Children: ADHD and Pediatric Mental Health, pub-
lished by Harvard University Press, 2009.
Drs. Mayes, Bagwell, and Erkulwater, University of Richmond, have disclosed that
they have no financial interests in any commercial companies pertaining to this editorial
content.
Ironically, neither the debate nor
ADHD and stimulants were new.
Methylphenidate, more commonly
known by the trade name Ritalin, was
first introduced in the United States in
1955, and approved by the Food and
Drug Administration in 1961 for use in
children with severe behavioral prob-
lems.10 Prior to Ritalin, another stimu-
lant (benzedrine) had been tested and
used by small numbers of children as
early as 1937.11 As for ADHD, the basic
symptoms of the disorder have gone by
several different diagnostic labels since
the early 1930s: “organic drivenness,”
“minimal brain damage,” “hyperkinetic
impulse disorder,” “minimal brain dys-
function,” “hyperkinesis,” “hyperactive
child syndrome,” and “attention deficit
disorder.”12 Even the core of the contro-
versy, children using physician-pre-
scribed psychoactive drugs, dates back
almost four decades. Nevertheless, neg-
ative publicity over the “drugging of
problematic children” in the early
1970s—together with another nega-
tive media blitz and a wave of lawsuits
against physicians, school personnel
and the American Psychiatric Associa-
tion in the late 1980s—greatly reduced
the prevalence of ADHD diagnoses and
pharmacotherapy compared with cur-
rent levels. When the 1990s began,
most schools across the country had
only a handful of (if any) children diag-
nosed with ADHD and using stimu-
lants.13 By 2000, most every classroom
in the United States had, on average, at
least one to two such students treated
for the disorder.4,14,15 Currently, almost
8% of youth aged 4 to 17 years have a
diagnosis of ADHD, and approximately
4.5% have the diagnosis and are taking
medication for the disorder.16,17
The massive increase in the number
of U.S. children diagnosed with ADHD
and using stimulants stemmed primar-
ily from a confluence of trends (clini-
cal, economic, educational, political),
an alignment of incentives (among cli-
nicians, educators, policy makers,
health insurers, the pharmaceutical in-
dustry), and the sizeable growth in sci-
entific knowledge about ADHD and
stimulants that converged in the first
half of the 1990s. Growing political
movements advocating for children’s
welfare and mental health consum-
ers,18-24 along with the decreasing stigma
associated with mental disorders, led to
three seemingly minor policy changes
in the early 1990s—to a federal income
support program (Supplemental Secu-
rity Income, SSI), a federal special edu-
cation program (Individuals with Dis-
abilities Education Act, IDEA), and a
joint federal-state public health insur-
ance program (Medicaid)—that
helped trigger the surge in ADHD diag-
noses and related stimulant use.25,26
ADHD and stimulant use have been
and remain controversial, in part be-
cause most children are diagnosed and
medicated as the result of decisions
made by their parents and clinicians. In
short, the treatment is ordinarily de-
cided for them instead of by them, a sce-
nario that invites criticism that a pa-
tient’s autonomy is being compromised
to some extent.27,28,29 Yet many medical
decisions involving children are made
this way and are not controversial.
Mental disorders such as ADHD, how-
ever, are different. They are regularly
diagnosed based mainly, if not solely, on
the presence of behavioral symp-
toms—inattentiveness, hyperactivity,
and impulsiveness—that are com-
mon—this despite the fact that the
DSM-IV outlines a far more extensive
and rigorous approach to making a
proper diagnosis of ADHD than relying
exclusively on rating an individual’s
symptoms. The key difference is one of
degree. Children with ADHD are sig-
nificantly more inattentive, impulsive,
distractible, and/or fidgety than their
peers, such that their symptoms cause
major personal impairment and inter-
fere with daily human functioning.30
At the same time, mental disorders
usually involve matters of degree, so
why has ADHD been more controver-
sial than other mental disorders? One of
the main reasons has to due with the
disorder’s dominant educational aspect.
The majority of ADHD diagnoses origi-
nate with the observations of a child’s
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teacher,31 and many of the disorder’s
symptoms—rated on behavioral
scales—require teacher reports to make
a diagnosis. The child
“often fails to give close attention
to details or makes careless mis-
takes in schoolwork, work, or
other activities,”
“often does not follow through
on instructions and fails to finish
schoolwork, chores, or duties in
the workplace,”
“often avoids, dislikes, or is re-
luctant to engage in tasks that re-
quire sustained mental effort
[such as school work or home-
work],”
“often leaves seat in classroom
or in other situations in which re-
maining seated is expected,”
“often blurts out answers before
questions have been com-
pleted”).”32-35
With ADHD, teachers are typically the
primary source of diagnostic informa-
tion.36 Only a minority of children with
the disorder exhibit symptoms during a
physician’s office visit.37,38
Similar to all mental disorders, how-
ever, there is no definitive medical test
(blood, urine, radiological) to verify an
ADHD diagnosis. Therefore, the diag-
nosis contains a large element of un-
avoidable subjectivity, which leaves it
open to competing definitions of what
is considered “normal” childhood be-
havior.39 The United States, for exam-
ple, consumes the majority of the
world’s production of stimulants with
school-age children using as much as
three times more psychiatric medica-
tion than children in the rest of the
world combined.40,41 In some European
countries, only a child psychiatrist can
prescribe a stimulant for a minor diag-
nosed with ADHD, while in other
countries the drugs can only be pre-
scribed if approved by three independ-
ent professionals.42 These regulations
have precluded a similar growth in
stimulant use in other developed coun-
tries, despite the fact that international
studies suggest that the prevalence of
ADHD is similar across different West-
ern countries when clinicians use
roughly the same diagnostic proce-
dures.43,44
For these and other reasons, people
debate whether the ADHD and stimu-
lant phenomenon in the U.S. is more
the story of medical science making
progress on a long misunderstood disor-
der or if ADHD has largely been “so-
cially constructed,” under the biological
vision of mental health, as a response to
non-medical problems such as un-
der-performing schools, increased aca-
demic demands and expectations, and
higher poverty and divorce rates than
existed before the 1970s.46 What makes
this question so contentious is that the
debate is political and philosophical in
nature because ADHD and stimulants
do not exist in a clinical vacuum.47,48 All
mental disorders and mental health
care, notes medical anthropologist By-
ron Good, are “social, psychological and
cultural to the core,” powerfully influ-
enced by public opinion and varying ex-
pectations of what is considered normal
and abnormal behavior by girls and boys
of very different ages and stages of devel-
opment.49 Meanwhile, teachers, parents,
clinicians, health plans, and pol-
icy-makers are all trying to deter-
mine—within their separate but over-
lapping spheres of influence—what is in
the best interests of literally millions of
children.
The Core of the Controversy
over ADHD and Stimulants
It seems virtually impossible to give a
presentation on or even just talk about
ADHD and stimulants without being
asked if the drugs are overused in the
United States. We assume that many
readers of this paper will have the same
curiosity. The answer is “yes” and “no.”
In some geographic areas and among
specific childhood populations, ADHD
appears to be over-diagnosed and the
drugs overused. However, several of the
same research findings that identify this
overuse also identify areas and popula-
tions in which ADHD is very likely
underdiagnosed and the drugs
underused with serious personal and
public health consequences.50-54
This more complicated and nuanced
reality of both over- and under-use of
stimulants is rarely presented in the
popular press, but it reflects two key fac-
tors. First, while a valid (real, genuine)
disorder, ADHD is also—similar to
many mental disorders—one that pri-
mary care physicians often diagnose in
a less than strictly thorough manner
due to the intense economic and time
constraints they face, as well as to their
training (or lack thereof) in the area of
mental disorders.55,56,57 This reality is im-
portant, because primary care physi-
cians make the majority of ADHD di-
agnoses and stimulant drug prescrip-
tions.58,59 In addition, it is not clear to
clinicians, researchers or the general
public if ADHD is primarily a medical
disorder, a behavioral problem mani-
festing primarily in schools, a mental
illness, or an evolutionary disorder of
human adaptation.60,61 It is also not
self-evident how hyper, inattentive,
and/or impulsive a child has to be to
warrant a diagnosis, because the bench-
mark of comparison for diagnosing a
child is whatever is considered “nor-
mal” for his or her peer age-group.
The ambiguity over ADHD’s classifi-
cation, and the manner in which it is
regularly diagnosed, contributes to sig-
nificant variation in diagnostic and
treatment styles by clinicians: preva-
lence rates for the disorder range from
as low as 2% to as high as 18% in differ-
ent communities across the United
States.62,63 This variation results in a se-
rious mismatch between the need for
and provision of pharmacotherapy,
with both “under-treatment” of
ADHD64 and the “over-use” of stimu-
lants by many children who do not
meet full ADHD diagnostic criteria (as
well as some children who exhibit no
symptoms of ADHD at all).53
The second factor that fuels the de-
bate is that stimulants are heavily regu-
lated Schedule II drugs, which are ef-
fective in helping individuals with or
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without ADHD.65,66 In other words,
they enhance most individuals’ ability
to sustain their level of concentra-
tion.67,68 This is not the way the public
understands medical interventions to
operate. The general view of medicines
is that they treat people with a chronic
or acute episode of illness or a disorder,
but that they would either have no ef-
fect or possibly be harmful to someone
who did not have an illness or a disor-
der. Consequently, when stimulants
help those with ADHD and enhance
the performance of individuals without
the disorder, they often invite skepti-
cism about the appropriateness of stim-
ulant use by millions of children.68
Even as scientific understanding of
ADHD advances, it is hard to imagine
the social and political controversy
over ADHD abating. As a diagnosis
and form of treatment, ADHD and
stimulant pharmacotherapy illustrate
both the success that science is capable
of producing—when applied to the
study of mental disorders—and its limi-
tations. Researchers have made tre-
mendous progress over the last three
decades in increasing our understand-
ing of ADHD, but when it comes to di-
agnosing most mental disorders our sys-
tem is still far behind other branches of
medicine, notes E. Jane Costello, a pro-
fessor of psychiatry and behavioral sci-
ences at Duke University. “On an indi-
vidual level, for many parents and fami-
lies, the experience can be a disaster; we
must say that.” For these families, the
search for a diagnosis is best seen as a
process of trial and error that may not
end with a definitive answer. If a family
can find some combination of treat-
ments that help a child improve,
Costello adds, “then the diagnosis may
not matter much at all.”69 ADHD is
more straightforward and easier to diag-
nosis in children than, for example, bi-
polar disorder or autism. Yet, as previ-
ously noted, diagnosing ADHD still re-
lies on some combination of interviews
with children (who often do not ex-
hibit symptoms in a clinician’s office or
are reluctant or unable to talk about
themselves the way an adult would),
behavioral checklists, less-than-precise
rating scales (that measure the exis-
tence and severity of ADHD symptoms
along the lines of “never,” “occasion-
ally,” “often,” “very often”), and reports
from teachers and parents.
Clinical Uncertainty and
Boundary Drawing
Ultimately, then, diagnosing and treat-
ing ADHD is still partially an art, de-
spite the fact that the science applied to
it has improved dramatically in recent
decades. At the heart of the contro-
versy over ADHD were questions of
boundary drawing. Children exhibit
symptoms of inattentiveness, hyperac-
tivity, and impulsiveness along a con-
tinuum. Despite the fact that scientific
research can inform our choices, where
the boundary between ADHD and typ-
ical childhood behavior is located is ul-
timately a political and social choice,
not a scientific one. No amount of clin-
ical research, therefore, can resolve this
question for us. Moreover, to the extent
that the boundary between sickness
and health is, in the case of mental dis-
orders such as ADHD, demarcated
without the ability to reference objec-
tive clinical signs or indicators of ill-
ness, debates about underdiagnosis or
overdiagnosis invariably tap into soci-
ety’s ambivalence about mental disor-
ders. The DSM was designed to identify
children with the severest symptoms,
those with the lowest levels of func-
tional ability. Yet the DSM is not ap-
plied in a vacuum: Social, political, and
economic forces impinge on where
physicians, educators, program admin-
istrators, and others decide to locate the
boundaries of medical dysfunction.
Criticisms of ADHD are criticisms both
of the limits of clinical knowledge and
of the extra-clinical forces that
influence diagnostic decision-making.
ADHD, of course, is not alone; the di-
agnoses of all mental disorders are subject
to influences outside of clinical medicine.
ADHD, however, is unique in the extent
to which it elicits intense reactions from
people. Because the symptoms of ADHD
are often most evident in the school set-
ting, where adults make sometimes tre-
mendous demands on children, some
critics worry that the identification of
children with the disorder is driven more
by the wants and expectations of teachers,
parents, and school administrators than by
theneedsof the students.More important,
because ADHD can be treated with phar-
maceutical medication produced by major
companies, other critics worry (for good
reason) about the influence of corporate
profit-seeking motives on the diagnosis of
children. ADHD is among the most visi-
ble and controversial mental disorders, in
short because it is a vehicle through which
many controversial social and political
trends can be criticized.
In the middle of this confusion are the
parents of children with ADHD. They
must decide whether to accept the label
of the disorder, and they must choose
which of the many forms of treatment
and school-based interventions to pur-
sue: behavioral therapy alone, medica-
tion alone, medication in combination
with behavioral therapy, which medica-
tion, which kinds of behavioral therapy.
The path to choose is far from evident,
and choices are constrained by
healthcare financing arrangements and
the attitudes of teachers and physicians
toward their children’s ADHD. In addi-
tion, critics like Peter Breggin and Phyllis
Schlafly write for a broad audience with
colorful anecdotes and pithy phrases, and
they publish their work in places that are
easily accessible to the general public.
Meanwhile, most researchers write for an
expert audience in specialized journals
and in language filled with clinical and
scientific jargon that lay readers might
find difficult to comprehend. As a result,
even with the advances in our under-
standing of the nature of ADHD and es-
pecially in our knowledge of effective
treatments brought about by extensive
research (including the Multimodal
Treatment Study of Children with
ADHD and numerous carefully designed
medication trials), parents often have
easier access to the vocal, and sometimes
extreme, views of critics of stimulant
treatment via the Internet and news re-
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ports than to the research published in
scientific journals. It is little surprise,
then, that despite the growth of scientific
knowledge of ADHD and stimulants,
parents are swayed by the extremists and
unsure about which treatment to pursue;
the misinformation that fills the public
debate over ADHD only serves to
heighten parents’ fear that they will
choose the wrong path. Thus, even if par-
ents decide to medicate their child, it is a
decision that can be fraught with guilt
and anxiety. Although other mental dis-
orders are difficult to diagnose with accu-
racy, although rates of childhood depres-
sion and other disorders are also on the
rise, and although the growing pediatric
use of psychotropic drugs is not limited to
stimulants, no other disorder touches
upon so many vexing social and political
questions, a situation that amplifies the
ambivalence that parents feel about med-
icating their children.
Rick Mayes and Catherine Bagwell are As-
sociate Professors of Psychology at the Uni-
versity of Richmond. Jennifer Erkulwater is
an Associate Professor of Political Science at
the University of Richmond.
CAPN • 5
References
1. Wolraich M. Attention deficit hyperactivity dis-
order: the most studied and yet the most contro-
versial diagnosis. Mental Retard Dev Disabil Res
Rev 1999;5:163-8.
2. Williams J., Klinepeter K. Palmes G., Pulley A.,
Foy J. Diagnosis and treatment of behavioral
health disorders in pediatric practice. Pediatrics
2004;114:601-6.
3. Rappley M. Attention-deficit hyperactivity disor-
der. N Engl J Med 2005;352:165-73.
4. Zuvekas S., Vitiello B., Norquist G. Recent trends
in stimulant medication use among u.s. children.
Am J Psychiatry 2006;163:579-85.
5. Bhatara V., Feil M., Hoagwood K., Vitiello B.,
Zima B. National trends in concomitant
psychotropic medication with stimulants in pedi-
atric visits: practice versus knowledge. J Atten
Disord 2004;7:217-26.
6. Robison L., Sclar D., Skaer T. Datapoints: trends
in ADHD and stimulant use among adults,
1995-2002. Psychiatric Serv 2005;56:1497.
7. Thomas C., Conrad P., Casler R., Goodman E.
Trends in the use of psychotropic medications
among adolescents, 1994 to 2001. Psychiatric Serv
2006;57:63-9.
8. Olfson M., Gameroff M., Marcus S., Jensen P. Na-
tional trends in the treatment of attention deficit
hyperactivity disorder. Am J Psychiatry
2003;160:1071-77.
9. Eberstadt M. Why ritalin rules. Policy Review
1999;94:24-44.
10. Chiarello R., Cole J. The use of
psychostimulants in general psychiatry: a recon-
sideration. Arch Gen Psychiatry 1987;44:286-95.
11. Bradley C. The behavior of children receiving
Benzedrine. Am J Psychiatry 1937;94:577-8.
12. Barkley R. Attention-deficit hyperactivity disorder:
A handbook for diagnosis and treatment. New York:
The Guilford Press, 1990.
13. Swanson J., Lerner M., Williams L. More fre-
quent diagnosis of attention-deficit hyperactivity
disorder. N Engl J Med 1995;333:944.
14. Schneider H., Eisenberg D. Who receives a diag-
nosis of attention-deficit/hyperactivity disorder
in the united states elementary school popula-
tion? Pediatrics 2006;117:601-9.
15. Spencer T., Biederman J., Mick E. Atten-
tion-deficit/hyperactivity disorder: diagnosis,
fifespan, comorbidities, and neurobiology. Ambul
Pediatr 2007;7:73-81.
16. Visser S., Lesesne C., Perou R. National esti-
mates and factors associated with medication
treatment for childhood attention-deficit/hyper-
activity disorder. Pediatrics Suppl
2007;119:S99-S106.
17. Centers for Disease Control and Prevention.
Mental health in the united states: prevalence of
diagnosis and medication treatment for atten-
tion-deficit/hyperactivity disorder. MMWR
Morb Mortal Wkly Rep 2005;54:842-7.
18. Scotch R. Politics and policy in the history of the
disability rights movement. Milbank Q
1989;67:380-400.
19. Sommer R. Family advocacy and the mental
health system: the recent rise of the alliance for
the mentally ill. Psychiatric Q 1990;61:205-21.
20. Tomes N. The patient as a policy factor: a histor-
ical case study of the consumer/survivor move-
ment in mental health. Health Aff
2006;25:720-9.
21. McLean A. Empowerment and the psychiatric
consumer/ex-patient movement in the united
states: contradictions, crisis and change. Soc Sci
Med 1995;40:1053-71.
22. Hatfield A. The national alliance for the men-
tally ill: a decade later. Community Mental Health
J 1991;27:95-103.
23. Minow M., Weissbourd R. Social movements for
children. Daedalus 1993;122:1-29.
24. Pfeiffer D. Overview of the disability movement:
history, legislative record, and political implica-
tions,” Policy Studies Journal 1993;21:724-34.
25. Perrin J., Kuhlthau K., McLaughlin T., Ettner S.,
Gortmaker S. Changing patterns of conditions
among children receiving supplemental security
income disability benefits. Arch Pediatr Adolesc
Med 1999;153:80-84.
26. Reid R., Maag J., Vasa S. Attention deficit hy-
peractivity disorder as a disability category: a cri-
tique. Exceptional Children 1994;60:198-214.
27. Hickey K., Lyckholm L. Child welfare versus pa-
rental autonomy: medical ethics, the law, and
faith-based healing. Theor Med Bioeth
2004;25:265-76.
28. Kuther T. Medical decision-making and minors:
issues of consent and assent. Adolescence
2003;38:343-58.
29. Sherer D. The capacities of minors to exercise
voluntariness in medical treatment decisions.
Law Hum Behav1991;15:431-49.
30. Goldman L., Genel M., Bezman R., Slanetz P.
Diagnosis and treatment of attention-deficit/hy-
peractivity disorder in children and adolescents:
council on scientific affairs, american medical as-
sociation. JAMA 1998;279:1100-07.
31. Sax L., Kautz K. Who first suggests the diagnosis
of attention-deficit/hyperactivity disorder? Ann
Fam Med 2003;1:171-4.
32. DuPaul G., Stoner G. ADHD in schools: assess-
ment and intervention strategies. New York: Guild-
ford Press, 2003.
33. Stein M., Marx N., Beard J., Lerner M., Levin B.,
Glascoe F., et al. ADHD: The diagnostic process
from different perspectives. J Dev Behav Pediatr
2004;25:53-8.
34. Biederman J., Faraone S., Monuteaux M.,
Grossbard J. How informative are parent reports
of attention-deficit/hyperactivity disorder symp-
toms for assessing outcome in clinical trials of
long-acting treatments? a pooled analysis of par-
ents’ and teachers’ reports. Pediat-
rics 2004;113:1667-71.
35. Biederman J., Gao H., Rogers A., Spencer T.
Comparison of parent and teacher reports of at-
tention-deficit/yperactivity disorder symptoms
from two placebo-controlled studies of
atomoxetine in children. Biol Psychiatry
2006;60:1106-10.
36. Havey J., Olson J., McCormick C., Cates G.
Teachers’ perceptions of the incidence and man-
agement of attention-deficit hyperactivity disor-
der. Appl Neuropsychol 2005;12:120-7.
37. Sleator E., Ullmann R. Can the physician diag-
nose hyperactivity in the office? Pediatrics
1981:67:13-7.
38. Johnson T. Evaluating the hyperactive child in
your office: is it ADHD? Am Fam Physician
1997;56:155-70.
39. Luhrmann T. Of two minds: the growing disorder in
american psychiatry. New York: Vintage, 2001.
40. Buitelaar J., Rothenberger A. Fore-
word—ADHD in the scientific and political con-
text. Eur Child Adolesc Psychiatry Suppl.
2004;13:11-6.
41. Hick H., Kaye J., Black C. Incidence and preva-
lence of drug-treated attention deficit disorder
among boys in the UK. Br J Gen Pract
2004;54:345-7.





43. Rohde L., Szobot C., Polanczyk G., Schmitz M.,
Martins S., Tramontina S. Attention-deficit/hy-
peractivity disorder in a diverse culture: do re-
search and clinical findings support the notion of
a cultural construct for the disorder? Biol Psychia-
try 2005;57:1436-41.
(continued on page 9)
CAPN • 9
Bupropion SR and Individual
Counseling
Efficacy of bupropion SR and individual
counseling as smoking cessation treat-
ments was assessed in a randomized, pla-
cebo-controlled clinical trial among
adult daily smokers. Intent-to-treat anal-
yses indicated that bupropion SR in-
creased abstinence rates at the end of
treatment. Bupropion SR treatment also
improved latency to lapse and relapse in
survival analyses. Counseling was not as-
sociated with increases in the likelihood
of abstinence at any time point.
McCarthy et al, A randomized controlled
clinical trial of bupropion SR and individual
smoking cessation counseling. Nicotine Tob
Res. 2008 Apr;10(4):717-29.
Effect of Genetic Polymorphisms
Even though bupropion is a first line
pharmacological agent for smoking cessa-
tion, not all smokers successfully quit
smoking by using bupropion. It means
other factors such as genetic predisposi-
tion could contribute to the therapeutic
outcome.
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